Skip to content

Regulatory Affairs Specialist

Prepare for pre-IND meeting with FDA

Enhances◐ 1–3 years

What You Do Today

Draft meeting request, briefing document with questions, proposed clinical plan — coordinate input from CMC, tox, clinical teams

AI That Applies

AI drafts briefing documents from existing data packages, generates meeting-ready Q&A, and identifies precedent from similar FDA meetings

Technologies

Veeva VaultGenerative AIClarivate Cortellis

How It Works

The system ingests existing data packages as its primary data source. A language model processes the input by identifying relevant context, generating appropriate responses, and structuring the output to match the expected format and domain conventions. The output — meeting-ready Q&A — surfaces in the existing workflow where the practitioner can review and act on it.

What Changes

Briefing document first draft takes days instead of weeks; AI surfaces how FDA responded to similar questions for comparable programs

What Stays

You craft the meeting strategy, decide which questions to ask, and prepare the team for FDA feedback scenarios

What To Do Next

This section won't tell you what your numbers should be. It will show you how to find them yourself. Every instruction below produces a real, verifiable result in your organization. No benchmarks, no projections — just the steps to build your own evidence.

1

Establish Your Baseline

Know where you are before you move

Before adopting AI tools for prepare for pre-ind meeting with fda, understand your current state.

•
Map your current process: Document how prepare for pre-ind meeting with fda works today — who does what, how long it takes, where the bottlenecks are. You need this baseline to measure improvement.
•
Identify the judgment points: You craft the meeting strategy, decide which questions to ask, and prepare the team for FDA feedback scenarios. These are the boundaries AI won't cross.
•
Assess your data readiness: AI tools for this area need data to work. Check whether your organization has the historical data, integrations, and data quality to support Veeva Vault tools.

Without a baseline, you can't measure whether AI actually improved anything. You'll adopt tools without knowing if they're working.

2

Define Your Measures

What to track and how to calculate it

Time per cycle

How to calculate

Measure how long prepare for pre-ind meeting with fda takes end-to-end today, then after AI adoption.

Why it matters

The most visible improvement is speed. If AI doesn't save time, question whether it's adding value.

Quality of output

How to calculate

Track error rates, rework frequency, or stakeholder satisfaction scores before and after.

Why it matters

Speed without quality is just faster mistakes. Measure both.

When to check: Check after 30 days of consistent use, then quarterly.
The commitment: Give new tools at least 30 days before judging. The first week is always awkward.
What NOT to measure: Don't measure AI adoption rate as a KPI. Adoption follows value — if the tool helps, people use it.
3

Start These Conversations

Who to talk to and what to ask

your Chief Compliance Officer

“What data do we already have that could improve how we handle prepare for pre-ind meeting with fda?”

They set the risk appetite for AI adoption in regulated processes

your legal counsel

“Who on our team has the deepest experience with prepare for pre-ind meeting with fda, and what tools are they already using?”

AI in compliance creates new regulatory interpretation questions

a regulatory affairs peer at another firm

“If we brought in AI tools for prepare for pre-ind meeting with fda, what would we measure before and after to know it actually helped?”

They can share how regulators are responding to AI-assisted compliance

4

Check Your Prerequisites

Confirm readiness before you invest

Check items as you confirm them.

← Back to AI for Regulatory Affairs Specialists